Sr. Leadership

点击翻译按钮获取中文摘要

SENIOR LEADERSHIP In March 2007 after 10 years of leading RPCI through significant and successful governance restructuring and programmatic expansion efforts, Dr. David Hohn retired as the President and CEO of Roswell Park Cancer Institute (RPCI). Dr. Hohn maintains a part-time position at RPCI as a senior advisor providing counsel to senior leadership on issues relevant to network development, facilities expansion planning and special projects. In addition, after 30 years of service, Dr. Youcef Rustum will be retiring from his role as Associate Director for Core Resources in the first quarter of 2008. In 2005, as Dr, Hohn and the Board of Directors (BOD) of RPCI began planning for a leadership transition, the possibility that Dr. Trump would succeed Dr. David Hohn as President and CEO and CCSG PI was raised. The BOD consulted both with Roswell Park leadership as well as an external panel of advisors. Based on this analysis, the BOD developed a succession plan for Dr. Trump's transition which began January 1, 2006 with his appointment to Associate Director of the Institute. The final phase of the transition occurred, as planned, on April 1, 2007 when Dr. Trump was named President and CEO. It is important to note that Dr. Trump was originally recruited to RPCI in 2002 as the Associate Director for Clinical Research and Co-leader of the Targeted Therapeutics Program at RPCI, positions he maintained until his the transition in 2006. Coupling Dr. Trump's leadership and experience with the detailed planning and execution of this succession plan has allowed for a smooth and effective transition of RPCI leadership. The change in the RPCI Director (Hohn) and two Associate Directors (Trump and Rustum) brought new senior leadership opportunities. With Dr. Trump's transition in 2006 to Associate Director of the Institute, Dr. Alex Adjei was recruited from the Mayo Clinic and appointed to the Associate Director for Clinical Research position. He is also the Chair for the Department of Medicine. Dr. Adjei brings a wealth of scientific and administrative leadership experience in cancer clinical research and will also lead the Molecular Targets and Experimental Therapeutics Program. Similarly, with Dr. Rustum's planned retirement and the departure of Virginia Opipare (Associate Director of Finance and Operations) in 2006, a unique opportunity became available to consolidate the responsibilities of these leadership roles into a single position to provide a more efficient and effective management of Institute operations. In early 2007, Dr. Trump recruited Jeff Walker, MBA from The Ohio State University (OSU) Comprehensive Cancer Center to a new role as the Associate Director for Administration. Mr. Walker brings more than 20 years of experience in leadership in academic/biomedical institutions, spending the last 6 years as the Associate Director for Administration of the OSU Comprehensive Cancer Center. Dr. Rustum will transition his responsibilities to Mr. Walker and remain as a Distinguished Professor and advisor to Dr. Trump and Mr. Walker. Early in 2007 Dr. Trump appointed Dr. Andrei Gudkov as the Associate Director for Basic Research replacing Dr. Michael Brattain who is leaving RPCI June, 2007. Dr. Gudkov, formerly Chairman of the Department of Molecular Genetics at the Lerner Research Institute, Cleveland Clinic Foundation, and a member of the Case Comprehensive Cancer Center, is internationally recognized for his pioneering work in gene and drug discovery. He directs a broad, highly collaborative NCI-funded program combining equally strong basic and translational components. Dr. Gudkov is also the Chair of the Cell Stress Biology Department. The 3 new senior leaders, Dr. Gudkov, Dr. Adjei, and Mr. Walker, bring fresh ideas and perspectives to the Institute as well as a wealth of scientific program development, and administrative leadership experience garnered from their involvement at other major NCI-designated cancer programs (Case Comprehensive Cancer Center, Mayo Clinic Cancer Center and the Ohio State University Comprehensive Cancer Center, respectively). Each of the Senior Leaders also plays a pivotal role in a CCSG Programs or Shared Resources. Dr. Adjei serves as Leader of the Molecular Targets and Experimental Therapeutics (MTET) and oversees Clinical Research Services, Dr. Gudkov is Leader of the Cell Stress and Biophysical Therapies (CSBT) Program, and Dr. James Marshall leads the Cancer Prevention and Population Sciences (CPPS) program. Dr. Candace Johnson is an active participant in the Prostate Program and MTET, while Dr. Trump participates in the Molecular Targets and Experimental Therapeutics Program. Mr. Walker serves as the CCSG Administrator and oversees the CCSG shared resources. All members of the Senior Leadership Team are active in the faculty recruitment process, serving as chairs or members of search committees. Further they are also involved in coordinating the EAB meetings, annual retreats, symposia/seminar series and participating in development activities. Each of these leaders is also active in national cancer research forums and well integrated into leadership and committee positions in these external arenas (ASCO, AACR, AACI, NCCN, NCI [caBIG, IRGs, parent committees]) assuring their awareness of and participation in deliberations regarding important national topics in cancer research, care and education and guaranteeing RPCI awareness of and leadership in the national trends. The Senior Leadership team interacts informally on a daily basis and meets formally on a weekly basis in the primary administrative leadership forum known as the RPCI Executive Council. Chaired by Dr. Trump, the Executive Council is the major decision-making body of the Institute, responsible for the on-going oversight of the RPCI and addressing all functional issues raised by its members. In addition, the Senior Leadership participates on the CCSG Steering Committee, a committee that meets monthly and includes the research program leaders as well as leaders of important CCSG and Institute initiatives [e.g., Imaging Development, Health Disparities]. The CCSG Steering Committee, chaired by Dr. Trump, provides a venue for strategic planning, program evaluation, membership review and approval and review of existing and proposed shared resources. Although there are several other venues where the Senior Leadership participates, it is through these two committees that primary decision-making is accomplished. There has been dramatic growth in RPCI during the last funding cycle. Over this funding cycle (2002 to 2006) the Senior Leadership team worked together to recruit more than 100 cancer investigators and clinicians, increase NCI funding by 74%, increase accruals to therapeutic investigator-initiated clinical trials and increase in out patient volume by 42% over this time period. As the number of cancer-focused basic, translational, clinical and population investigators at the RPCI have grown, four new Shared Resources have been established to support the needs of the membership with three more now in development. It is anticipated that the current Senior Leadership team will continue this successful trajectory via developing and executing longterm vision and strategic planning for the Institute.